On commonness and rarity of thyroid hormone resistance: A discussion based on mechanisms of reduced sensitivity in peripheral tissues

Medical Hypotheses

Volumn 69, Issue 4, 2007, Pages 913-921

  Tjorve E ^a   Tjorve K M C ^a   Olsen, J O ^a   Senum, R ^a   Oftebro, H ^a  

^a INLAND NORWAY UNIVERSITY OF APPLIED SCIENCES   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ARTICLE; AUTOIMMUNITY; CELL NUCLEUS; CHEMICAL ANALYSIS; CYTOSOL; EUTHYROIDISM; FUNCTIONAL GENOMICS; HORMONE ACTION; HORMONE METABOLISM; HORMONE SENSITIVITY; HUMAN; HYPOTHYROIDISM; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SENSITIVITY ANALYSIS; THYROID HORMONE RESISTANCE; TRANSCRIPTION INITIATION;

BIOLOGICAL TRANSPORT; CELL NUCLEUS; CYTOSOL; HUMANS; HYPOTHYROIDISM; IMMUNITY, NATURAL; INCIDENCE; MODELS, BIOLOGICAL; THYROID HORMONE RESISTANCE SYNDROME; THYROID HORMONES; TRANSCRIPTION, GENETIC;

EID: 34547852280     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.12.056     Document Type: Article

References (85)

1. Albright F., Burnett C.H., Smith P.H., and Parson W. Pseudohypoparathyroidism: an example of Seabright-Bantam syndrome. Endocrinology 30 (1942) 922-932
2. Barnes B.O. Basal temperature versus basal metabolism. JAMA 119 (1942) 1072-1074
3. Refetoff S. 2004. Resistance to thyroid hormone, chapter 16d. In: De Groot LJ, Hennemann G, editors. Thyroid Dis Manager. [accessed 28.08.2006], p. 36.
4. Hauser P., McMillin M., and Bhatara V.S. Resistance to thyroid hormone: implications for neurodevelopmental research on the effects of thyroid hormone disrupters. Toxicology Ind Health 14 1/2 (1998) 85-101
5. Bakker O., and Wiersinga W.M. Resistance to thyroid hormone. Thyroid Int 3 (2001) 1-16
6. Yen P.M. Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab 14 7 (2003) 327-333
7. Beck-Peccoz P., and Perzani L. Syndrome of hormone resistance in thyroid field. Revue del'ACOMEN 5 3 (1999) 298-299
8. Kaplan M.M., Swartz S.L., and Larsen P.R. Partial peripheral resistance to thyroid hormone. Am J Med 70 (1981) 1115-1121
9. Dumitrescu AM, Refetoff S. Multiple etiologies for reduced sensitivity to thyroid hormone. Hot thyroidology (), January, No 2, 2006.
10. Rao G.S., Eckel J., Rao M.L., and Breuer H. Uptake of thyroid hormone by isolated rat liver cells. Biochem Biophys Res Commun 73 (1976) 98-104
11. Krenning E.P., Docter R., Bernard H.F., Visser T.J., and Hennemann G. Active transport of triiodothyronine (T3) into isolated rat liver cells. FEBS Lett 91 (1978) 113-116
12. Hennemann G., Everts M.E., de Jong M., Lim C.F., Krenning E.P., and Docter R. The significance of plasma membrane transport in the bioavailability of thyroid hormone. Clin Endocrinol 48 (1998) 1-8
13. Ritchie J.W.A., Shi Y.B., Hyashi Y., Baird F.E., Muchekehu R.W., Christie G.R., et al. A role for thyroid hormone transporters in transcriptional regulation by thyroid hormone receptors. Mol Endocrinol 17 4 (2003) 653-661
14. Dumitrescu A.M., Liao X.H., Best T.B., Brockmann K., and Refetoff S. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet 74 (2004) 168-175
15. Friesema E.C., Grueters A., Biebermann H., Krude H., von Moers A., Reeser M., et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 364 (2004) 1435-1437
16. Schwartz C.E., May M.M., Carpenter N.J., Rogers R.C., Martin J., Bialer M.G., et al. Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene. Am J Hum Genet 77 (2005) 41-53
17. Maranduba C.M., Friesema E.C., Kok F., Kester M.H.A., Jansen J., Setrié A.L., et al. Decreased cellular T3 uptake and metabolism in Allan-Herndon-Dudley syndrome (AHDS) due to a novel mutation in the MCT8 thyroid hormone transporter. J Med Genet 43 (2005) 457-460
18. Movius E.G., Phyillaier M.M., and Robbins J. Phloretin inhibits cellular uptake and nuclear receptor binding of triiodothyronine in human hep G2 hepatocarcinoma cells. Endocrinology 124 4 (1989) 1988-1997
19. Friesma E.C.H., Docter R., Moerings E.P.C.M., Verry F., Krenning E.P., Hennemann G., et al. Thyroid hormone transport by the heterodimeric human system L amino acid transporter. Endocrinology 142 10 (2001) 4339-4348
20. Sarne D. Effects of drugs, disease, and other agents on thyroid function, chapter 5a. In: De Groot LJ, Hennemann G, editors. Thyroid Dis Manager, 2004. [accessed 28.08.2006], p. 56.
21. Fujiwara K., Adachi H., Nishio T., Unno M., Tokui T., Okabe M., et al. Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology 142 (2001) 2005-2012
22. Ritchie J.W., and Taylor P.M. Role of the system L permease LAT1 in amino acid and iodothyronine transport in placenta. Biochem J 356 (2001) 719-725
23. Visser TG. Metabolism of thyroid hormone, chapter 3c. In: De Groot LJ, Hennemann G, editors. Thyroid Dis Manager. 2004 [accessed 28.08.2006], p. 20.
24. Hennemann G, Visser T, Cell uptake of hormone, chapter 3b. In: De Groot LJ, Hennemann G, editors. Thyroid Dis Manager. , 2005. [accessed 28.08.2006], p. 20.
25. De Groot LJ. The nonthyroidal illness syndrome, chapter 5b. In: Thyroid Dis Manager. De Groot LJ, Hennemann G, editors. , 2005. [accessed 28.08.2006], p. 28.
26. Hennemann G., Vos R.A., de Jong M., Krenning E.P., and Docter R. Decreased peripheral 3,5,3′-triiodothyronine (T3) production from thyroxine (T4): a syndrome of impaired thyroid hormone activation due to transport inhibition of T4 into T3-producing tissues. J Clin Endocrinol Metabol 77 (1993) 1431-1435
27. van der Heyden J.T., Docter R., van Toor H., Wilson J.H., Hennemann G., and Krenning E.P. Effects of caloric deprivation on thyroid hormone tissue uptake and generation of low-T3 syndrome. Am J Physiol 251 (1986) E156-E163
28. Bianco A.C., Gereben D.S.B., Berry M.J., and Larsen P.R. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Rev 3 1 (2002) 38-89
29. Copeland P.R. Regulation of gene expression by stop codon recoding: selenocysteine. Gene 312 (2003) 17-25
30. Dumitrescu A.M., Liao X.H., Abdullah M.S.Y., Lado-Abeal J., Majed F.A., Moeller L.C., et al. Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Nat Genet 37 (2005) 1247-1252
31. Harris A.R.C., Fang S.L., Vagenakis A.G., and Braverman L.E. Effect of starvation, nutriment replacement, and hypothyroidism on in vitro hepatic T4 to T3 conversion in the rat. Metabolism 27 (1978) 1680-1690
32. Vagenakis A.G., Portnay G.I., O'Brian J.T., Rudolph M., Arky R.A., Ingbar S.H., et al. Effect of starvation on e production and metabolism of thyroxine and triiodothyronine in euthyroid obese patients. J Clin Endocrinol Metab 45 (1977) 1305-1309
33. Suda A.K., Pittman C.S., Shimizu T., and Chambers Jr. J.B. The production and metabolism of 3,5,3′-triiodothyronine and 3,3′,5′-triiodothyronine in normal and fasting subjects. J Clin Endocrinol Metab 47 6 (1978) 1311-1319
34. Scanlan T.S., Suchland K.L., Hart M.E., Chiellini G., Huang Y., Kruzich P.J., et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 10 6 (2004) 582-583
35. Moeller LC, Cao X, Dimitrescu AM, Seo H, Refetoff S. Thyroid hormone mediated changes in gene expression can be initiated by cotosolic action of the thyroid hormone receptor b through the phospatidylinosotol 3-kinase pathway. Nuclear Receptor Signaling () 2006; 4 DOI:10/nrs.04020. p. 4.
36. Benvenga S., Lakshmanan M., and Trimarchi F. Carnitine is a naturally occurring inhibitor of thyroid hormone nuclear uptake. Thyroid 10 12 (2000) 1043-1050
37. Benvenga S., Ruggeri R.M., Russo A., et al. Usefulness of l-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 86 (2001) 3579-3594
38. Torchia J., Glass C., and Rosenfeld M.G. Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol 10 (1998) 373-383
39. McKenna N.J., Lanz R.B., and O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20 (1999) 321-344
40. Zhang J., and Lazar M.A. The mechanism of action of THs. Annu Rev Physiol 62 (2000) 439-466
41. Yen P.M. Physiological and molecular basis of TH action. Physiol Rev 81 (2001) 1097-1142
42. Harvey C.B., and Williams G.R. Mechanism of TH action. Thyroid 12 (2002) 441-446
43. Santos G.M., Pantoja C.J., eSilva A.C., Rodrigues M.C., Ribeiro R.C., Simeoni L.A., et al. Thyroid hormone receptor binding to DNA and T3-dependent transcriptional activation are inhibited by uremic toxins. Nucl Receptor 3 1 (2005) 1 10.1186/1478-1336-3-1
44. Pohlenz J., Weiss R.E., Maccia P.E., Pannain S., Lau I.P.T., Ho H., et al. Five new families with resistance to thyroid hormone not cause by mutations in the thyroid hormone receptor gene. J Clin Endocrinol Metabol 84 11 (1999) 3919-3928
45. Vliet E.L. Screaming to be heard: hormonal connections women suspect and doctors ignore (1995), M Evans & Co, New York
46. DeGroot L.J., and Rue P.A. Roentgenographic contrast agents inhibit triiodothyronine binding to nuclear receptors in vitro. J Clin Endocrinol Metab 49 (1979) 538-542
47. Vorperian V.R., Havighurst T.C., Miller S., and January C.T. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 30 (1997) 791-798
48. Hahn C.G., Pawlyk A.C., Whybrow P.C., Gyulai L., and Tejani-Butt S.M. Lithium administration affects gene expression of thyroid hormone receptors in rat brain. Life Sci 64 (1999) 1793-1802
49. Yen PM. 2006 Celluar action of thyroid hormone, chapter 3d. In: De Groot LJ, Hennemann G, editors. Thyroid Dis Manager. [accessed 28.08.2006], p. 26.
50. Engelbienne P., Verhas M., Herst C., and De Meirleir K. Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasomes: possible etiology for unexplained chronic fatigue. Medical Hypotheses 60 (2003) 175-180
51. Carella C., Mazziotti G., Amato G., Braverman L.E., and Roti E. Interferon-α-related thyroid disease: pathophysiological, epidemiological and clinical aspects. J Clin Endocrinol Metab 89 8 (2004) 3656-3661
52. Fonseca V., Thomas M., and Dusheiko G. Thyrotropin receptor antibodies following treatment with recombinant alpha-interferon in patients with hepatitis. Acta Endocrionol (Copenh) 125 (1991) 491-493
53. Dusso A.S. Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int Suppl 85 (2003) 6-9
54. De Groot L.J., Coleoni A.H., Rue P.A., Seo H., Martino E., and Refetoff S. Reduced nuclear triiodothyronine receptors in starvation-induced hypothyroidism. Biochem Bioophys Res Commun 79 (1977) 173-178
55. Tagami T., Nakamura H., Sasaki S., Miyoshi Y., and Nakao K. Starvation-induced decrease in the maximal binding capacity for triiodothyronine of the thyroid hormone receptor due to a decrease on the receptor protein. Metabolism 45 (1996) 970-973
56. Iwakasi T., Miyazaki W., Takeshita A., Kuroda Y., and Koibuchi N. Polychlorinated biphenyls suppress thyroid hormone-induced transactivation. Biochem Biophys Res Commun 299 3 (2002) 384-388
57. Miyazaki W., Iwasaki T., Takeshita A., Kuroda A., and Koibuchi N. Polychlorinated biphenyls suppress thyroid hormone receptor-mediated transcription through a novel mechanism. J. Biol. Chem 279 18 (2004) 18195-18202
58. Richenbacher U., McKinney J.D., Oatley S.J., and Blake C. Structurally specific binding of halogenated biphenyls to thyroxine transport protein. J Med Chem 29 (1986) 641-648
59. Moore J.M.R., and Guy R.K. Coregulator interactions with the thyroid hormone receptor. Mol Cell Proteom 4 (2005) 475-482
60. Weiss R.E., Xu J., Ning G., Pohlenz J., O'Malley B.W., and Refetoff S. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J 18 (1999) 1900-1904
61. Kyle L.H. Clinical applications of the basal metabolism test. Med Clin North Am 34 (1950) 1839-1851
62. Horting H., and Hiisi-Brummer L. Basal metabolic rate and serum protein-bound iodine in thyroid disturbances with special reference to goiter and 'hypometabolism'. Acta Med Scand 165 (1959) 403-411
63. Tata J.R., Ernsten L., and Lindberg O. Control of basal metabolic rate by thyroid hormones and cellular function. Nature 193 (1962) 1058-1060
64. Escobar del Rey F., Ruiz de Ona C., Bernal J., Obregon M.J., and Morreale de Escobar G. Generalized deficiency of 3,5,3′-triiodo-L-thyronine (T3) in tissues from rats on a low iodine intake, despite normal circulating T3 levels. Acta Endocrinol (Copenh) 120 4 (1989) 490-498
65. De Groot L.J. Dangerous dogmas in medicine: the nonthyoroidal illness syndrome. J Clin Endicrinol Metab 84 (1999) 151-164
66. Brennan M.D., Klee G.G., Preissner C.M., and Hay I.D. Heterophilic serum antibodies: a cause for falsely elevated serum thyrotropin levels. Mayo Clin Proc 62 (1987) 894-898
67. Wood J.M., Gordon D.L., Rudinger A.N., and Brooks M.M. Artifactual elevation of thyroid-stimulating hormone. Am J Med 90 (1991) 261-262
68. Zweig M.H., Csako G., Reynolds J.C., and Carrasquillo J.A. Interference by iatrogenically induced anti-mouse IgG antibodies in a two-site immunometric assay for thyrotropin. Arch Path Rad Metab 1165 (1991) 164-168
69. Williams G.R. Cloning and characterization of two novel thyroid hormone receptor β isoforms. Mol Cell Biol 20 (2000) 8329-8342
70. Boelert K., and Franklyn J.A. Thyroid hormone in health and disease. J Endocrinol 187 (2005) 1-15
71. Garrison R.L., and Breeding P.C.A. Metabolic basis for fibromyalgia and its related disorders: the possible role of resistance to thyroid hormone. Medical Hypotheses 61 2 (2003) 182-189
72. McDonagh J.E., and Isenberg D.A. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis 59 (2000) 230-232
73. Chan A.T.Y., Al-Saffar Z., and Bucknall R.C. Thyroid disease in systemic lupus erythematosus and rheumatoid arthritis. Rheumatology 40 (2001) 353-354
74. Pyne D., and Isenberg D.A. Autoimmune thyroid disease in systemic lupus. Ann Rheum Dis 61 (2002) 70-72
75. Sridhar G.R., and Nagamani G. Clinical association of autoimmune diseases with diabetes mellitus. Ann NY Acad Sci 958 (2002) 390-392
76. Innocencio R.M., Romaldini J.H., and Ward L.S. Thyroid autoantibodies in autoimmune diseases. Medicina (B Aires) 64 (2004) 227-230
77. Lazarus M.N., and Isenberg D.A. Development of additional autoimmune diseases in a population of patients with primary Sjögren's syndrome. Ann Rheum Dis 64 (2005) 1062-1064
78. Sloka J.S., Pryse-WEM P., Stefanelli M., and Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J Autoimmune Dis 2 (2005) 9 10.1186/1740-2557-2-9
79. Stagi S., Giani T., Siminini G., and Falcini F. Thyroid function, autoimmune thyroiditis and coeliac disease in juvenile idiopathic arthritis. Rheumatology 44 4 (2005) 517-520
80. Szyper-Kravitz M., Marai I., and Shoenfeld Y. Coexistence of thyroid autoimmunity with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of autoimmunity. Autoimmunity 38 3 (2005) 247-255
81. Calzi L.L., Benevenga S., Battiato S., Santini F., and Trimarchi F. Autoantibodies to thyroxin and triiodothyronine in the immunoglobulin G fraction of serum. Clin Chem 34 (1988) 2561-2562
82. Alemzadeh R., Friedman S., Fort P., Reker B., and Lifshitz F. Is there compensated hypothyroidism in infancy?. Pediatrics 90 2 (2001) 207-211
83. Taniyama M., Honma K., and Ban Y. Urinary cortisol metabolites in the assessment of peripheral thyroid hormone action: application for diagnosis of resistance to thyroid hormone. Thyroid 3 3 (1993) 229-233
84. Vantyghem M.C., Ghulam A., Hober C., Schoonberg C., D'Herbomez M., Racadot A., et al. Urinary cortisol metabolites in the assessment of peripheral thyroid hormone action: overt and subclinical hypothyroidism. J Endocrinol Invest 21 4 (1998) 219-225
85. Bodenner D.L., and Lash R.W. Thyroid disease mediated by molecular defects in cell surface and nuclear receptors. Am J Med 105 6 (1998) 524-538